1. Home
  2. MDAIW vs NCMI Comparison

MDAIW vs NCMI Comparison

Compare MDAIW & NCMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDAIW
  • NCMI
  • Stock Information
  • Founded
  • MDAIW N/A
  • NCMI 2005
  • Country
  • MDAIW United States
  • NCMI United States
  • Employees
  • MDAIW 78
  • NCMI N/A
  • Industry
  • MDAIW Medical/Dental Instruments
  • NCMI Advertising
  • Sector
  • MDAIW Health Care
  • NCMI Consumer Discretionary
  • Exchange
  • MDAIW Nasdaq
  • NCMI Nasdaq
  • Market Cap
  • MDAIW N/A
  • NCMI N/A
  • IPO Year
  • MDAIW N/A
  • NCMI 2007
  • Fundamental
  • Price
  • MDAIW $0.31
  • NCMI $5.07
  • Analyst Decision
  • MDAIW
  • NCMI Strong Buy
  • Analyst Count
  • MDAIW 0
  • NCMI 5
  • Target Price
  • MDAIW N/A
  • NCMI $7.60
  • AVG Volume (30 Days)
  • MDAIW 35.6K
  • NCMI 867.7K
  • Earning Date
  • MDAIW 02-27-2025
  • NCMI 05-06-2025
  • Dividend Yield
  • MDAIW N/A
  • NCMI 1.18%
  • EPS Growth
  • MDAIW N/A
  • NCMI N/A
  • EPS
  • MDAIW N/A
  • NCMI N/A
  • Revenue
  • MDAIW $27,264,000.00
  • NCMI $238,300,000.00
  • Revenue This Year
  • MDAIW N/A
  • NCMI $15.11
  • Revenue Next Year
  • MDAIW N/A
  • NCMI $9.16
  • P/E Ratio
  • MDAIW N/A
  • NCMI N/A
  • Revenue Growth
  • MDAIW 44.52
  • NCMI 42.10
  • 52 Week Low
  • MDAIW $0.08
  • NCMI $4.12
  • 52 Week High
  • MDAIW $0.90
  • NCMI $7.60
  • Technical
  • Relative Strength Index (RSI)
  • MDAIW N/A
  • NCMI 34.36
  • Support Level
  • MDAIW N/A
  • NCMI $4.12
  • Resistance Level
  • MDAIW N/A
  • NCMI $5.88
  • Average True Range (ATR)
  • MDAIW 0.00
  • NCMI 0.32
  • MACD
  • MDAIW 0.00
  • NCMI -0.08
  • Stochastic Oscillator
  • MDAIW 0.00
  • NCMI 46.12

About MDAIW Spectral AI Inc.

Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.

Share on Social Networks: